FY2025 Earnings Estimate for ZVRA Issued By HC Wainwright

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – HC Wainwright cut their FY2025 earnings per share estimates for Zevra Therapeutics in a report issued on Thursday, March 13th. HC Wainwright analyst O. Livnat now expects that the company will post earnings of ($0.32) per share for the year, down from their prior forecast of ($0.23). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2026 earnings at $0.58 EPS, FY2027 earnings at $1.48 EPS, FY2028 earnings at $1.99 EPS and FY2029 earnings at $2.51 EPS.

Other analysts have also issued research reports about the company. JMP Securities set a $18.00 target price on Zevra Therapeutics in a report on Wednesday, March 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group boosted their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Finally, Guggenheim boosted their price target on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $22.29.

Zevra Therapeutics Stock Performance

ZVRA opened at $7.97 on Monday. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76. The firm has a market capitalization of $431.30 million, a PE ratio of -4.05 and a beta of 1.98. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The business’s 50-day simple moving average is $7.92 and its 200 day simple moving average is $8.17.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million.

Insider Buying and Selling

In related news, CFO R. Laduane Clifton sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the transaction, the chief financial officer now directly owns 51,361 shares of the company’s stock, valued at approximately $403,697.46. This represents a 17.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joshua Schafer sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $82,530.00. Following the transaction, the executive vice president now directly owns 29,486 shares in the company, valued at approximately $231,759.96. This trade represents a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is owned by company insiders.

Institutional Trading of Zevra Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets purchased a new stake in shares of Zevra Therapeutics in the fourth quarter worth approximately $53,000. XTX Topco Ltd purchased a new stake in shares of Zevra Therapeutics during the third quarter valued at approximately $94,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Zevra Therapeutics during the fourth quarter valued at approximately $94,000. Intech Investment Management LLC purchased a new stake in shares of Zevra Therapeutics during the third quarter valued at approximately $95,000. Finally, Virtu Financial LLC purchased a new stake in shares of Zevra Therapeutics during the third quarter valued at approximately $127,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.